Relevant bibliographies by topics / Application to cancer therapy

Academic literature on the topic 'Application to cancer therapy'

Author: Grafiati
Published: 9 March 2023
Last updated: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Application to cancer therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Application to cancer therapy"

1

MBBS MD, Dr Asmita Jain. "Metformin in Cancer Prevention and Therapy: New Application of an Old Drug." Journal of Medical Science And clinical Research 05, no. 04 (April 14, 2017): 20333–37. http://dx.doi.org/10.18535/jmscr/v5i4.97.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Misra, Ranjita, Sarbari Acharya, and Sanjeeb K. Sahoo. "Cancer nanotechnology: application of nanotechnology in cancer therapy." Drug Discovery Today 15, no. 19-20 (October 2010): 842–50. http://dx.doi.org/10.1016/j.drudis.2010.08.006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Setayesh-Mehr, Zahra, and Mahdiye Poorsargol. "Toxic proteins application in cancer therapy." Molecular Biology Reports 48, no. 4 (April 2021): 3827–40. http://dx.doi.org/10.1007/s11033-021-06363-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Akiyode, O., D. George, J. Boateng, and G. Getti. "Application of Biosurfactants in Cancer Therapy." Annals of Oncology 26 (March 2015): ii28. http://dx.doi.org/10.1093/annonc/mdv095.4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Koohi Moftakhari Esfahani, Maedeh Koohi Moftakhari, Seyed Ebrahim Alavi, Peter J. Cabot, Nazrul Islam, and Emad L. Izake. "Application of Mesoporous Silica Nanoparticles in Cancer Therapy and Delivery of Repurposed Anthelmintics for Cancer Therapy." Pharmaceutics 14, no. 8 (July 29, 2022): 1579. http://dx.doi.org/10.3390/pharmaceutics14081579.

Full text
Abstract:
This review focuses on the biomedical application of mesoporous silica nanoparticles (MSNs), mainly focusing on the therapeutic application of MSNs for cancer treatment and specifically on overcoming the challenges of currently available anthelmintics (e.g., low water solubility) as repurposed drugs for cancer treatment. MSNs, due to their promising features, such as tunable pore size and volume, ability to control the drug release, and ability to convert the crystalline state of drugs to an amorphous state, are appropriate carriers for drug delivery with the improved solubility of hydrophobic drugs. The biomedical applications of MSNs can be further improved by the development of MSN-based multimodal anticancer therapeutics (e.g., photosensitizer-, photothermal-, and chemotherapeutics-modified MSNs) and chemical modifications, such as poly ethyleneglycol (PEG)ylation. In this review, various applications of MSNs (photodynamic and sonodynamic therapies, chemotherapy, radiation therapy, gene therapy, immunotherapy) and, in particular, as the carrier of anthelmintics for cancer therapy have been discussed. Additionally, the issues related to the safety of these nanoparticles have been deeply discussed. According to the findings of this literature review, the applications of MSN nanosystems for cancer therapy are a promising approach to improving the efficacy of the diagnostic and chemotherapeutic agents. Moreover, the MSN systems seem to be an efficient strategy to further help to decrease treatment costs by reducing the drug dose.
APA, Harvard, Vancouver, ISO, and other styles
6

Ko, Jeong-Hyeon, Seok-Geun Lee, Woong Yang, Jae-Young Um, Gautam Sethi, Srishti Mishra, Muthu Shanmugam, and Kwang Ahn. "The Application of Embelin for Cancer Prevention and Therapy." Molecules 23, no. 3 (March 9, 2018): 621. http://dx.doi.org/10.3390/molecules23030621.

Full text
Abstract:
Embelin is a naturally-occurring benzoquinone compound that has been shown to possess many biological properties relevant to human cancer prevention and treatment, and increasing evidence indicates that embelin may modulate various characteristic hallmarks of tumor cells. This review summarizes the information related to the various oncogenic pathways that mediate embelin-induced cell death in multiple cancer cells. The mechanisms of the action of embelin are numerous, and most of them induce apoptotic cell death that may be intrinsic or extrinsic, and modulate the NF-κB, p53, PI3K/AKT, and STAT3 signaling pathways. Embelin also induces autophagy in cancer cells; however, these autophagic cell-death mechanisms of embelin have been less reported than the apoptotic ones. Recently, several autophagy-inducing agents have been used in the treatment of different human cancers, although they require further exploration before being transferred from the bench to the clinic. Therefore, embelin could be used as a potential agent for cancer therapy.
APA, Harvard, Vancouver, ISO, and other styles
7

Wang, Jiawei, Yan Bao, and Yandan Yao. "Application of Bionanomaterials in Tumor Immune Microenvironment Therapy." Journal of Immunology Research 2021 (February 10, 2021): 1–10. http://dx.doi.org/10.1155/2021/6663035.

Full text
Abstract:
Targeted therapy for the cancer immune system has become a clinical reality with remarkable success. Immune checkpoint blockade therapy and chimeric antigen receptor T-cell (CAR-T) immunotherapy are clinically effective in a variety of cancers. However, the clinical utility of immunotherapy in cancer is limited by severe off-target toxicity, long processing time, limited efficacy, and extremely high cost. Bionanomaterials combined with these therapies address these issues by enhancing immune regulation, integrating the synergistic effects of different molecules, and, most importantly, targeting and manipulating immune cells within the tumor. In this review, we will summarize the most current researches on bionanomaterials for targeted regulation of tumor-associated macrophages, myeloid-derived suppressor cells, dendritic cells, T lymphocyte cells, and cancer-associated fibroblasts and summarize the prospects and challenges of cell-targeted therapy and clinical translational potential in a tumor immune microenvironment in cancer treatment.
APA, Harvard, Vancouver, ISO, and other styles
8

Wang, Sumei, Shunqin Long, and Wanyin Wu. "Application of Traditional Chinese Medicines as Personalized Therapy in Human Cancers." American Journal of Chinese Medicine 46, no. 05 (January 2018): 953–70. http://dx.doi.org/10.1142/s0192415x18500507.

Full text
Abstract:
Although lots of great achievements have been gained in the battle against cancer during the past decades, cancer is still the leading cause of death in the world including in developing countries such as China. Traditional Chinese medicine (TCM) is popular in Chinese and East Asian societies as well as some other Western countries and plays an active role in the modern healthcare system including patients with cancer, which may act as a potential effective strategy in treating human cancers. In this review, we aimed to introduce the mechanisms of TCM compound, as an option of individualized therapy, in treating cancer patients from the perspective of both Chinese and Western medicine. In the view of traditional Chinese medicine theory, individualized treatment for human cancers based on syndrome type benefits the cancer patients with personalized conditions. Balancing Qi, Xue, Yin and Yang, eliminating phlegm and removing dampness is how TCM compound functions on cancer patients. While in the view of Western medicine, inhibiting cancer cell growth and metastasis as well as improving immune status is how herbal compounds act on cancer patients. We also summarized the applications of TCM compound in human cancers, which will shed light on the clinical application of TCM compound on patients with cancer. TCM compound could be used as a complementary and alternative medicine (CAM) in human cancers. It could be applied in cancer patients with cancer-related fatigue (CRF). In addition, it is a good method for alleviating the side effects of both radiotherapy and chemotherapy. Therefore, TCM compound plays a critical role in treating patients with cancer, which has a promising strategy in the field of cancer management.
APA, Harvard, Vancouver, ISO, and other styles
9

Ivanovic, Vesna. "Transforming growth factor-β: Biology and application to cancer therapy." Archive of Oncology 17, no. 3-4 (2009): 61–64. http://dx.doi.org/10.2298/aoo0904061i.

Full text
Abstract:
Transforming growth factor-? (TGF-?), an extensively investigated cytokine, plays a very important role in promoting the spread of cancers in the body, and can play a direct role in facilitating metastasis. Consequently, TGF-? is currently explored as a prognostic candidate biomarker of tumor invasiveness and metastasis. Therefore, in clinical scenarios involving increased TGF-? activity, attempts to decrease or abrogate TGF-? signaling could be used as a therapy for advanced or metastatic disease. It follows that TGF-? signaling offers an attractive target for cancer therapy. Several anti-TGF-? approaches, such as TGF-? antibodies, antisense oligonucleotides and small molecules inhibitors of TGF-? type 1 receptor kinase, have shown great promise in the preclinical studies. These studies, coupled with progressing clinical trials indicate that inhibition of TGF-? signaling may be indeed a viable option to cancer therapy. This review summarizes the TGF-? biology, screening cancer patients for anti-TGF-? therapy, and several strategies targeted against TGF-? signaling for cancer therapy. The next several years promise to improve our understanding of approaching cancer therapy by further evaluation of TGF-? signaling inhibitors for clinical efficacy. The complexity of TGF-? biology guarantees that many surprises lie ahead.
APA, Harvard, Vancouver, ISO, and other styles
10

Sargazi, Saman, Ushna Laraib, Simge Er, Abbas Rahdar, Mohadeseh Hassanisaadi, Muhammad Nadeem Zafar, Ana M. Díez-Pascual, and Muhammad Bilal. "Application of Green Gold Nanoparticles in Cancer Therapy and Diagnosis." Nanomaterials 12, no. 7 (March 27, 2022): 1102. http://dx.doi.org/10.3390/nano12071102.

Full text
Abstract:
Nanoparticles are currently used for cancer theranostics in the clinical field. Among nanoparticles, gold nanoparticles (AuNPs) attract much attention due to their usability and high performance in imaging techniques. The wide availability of biological precursors used in plant-based synthesized AuNPs allows for the development of large-scale production in a greener manner. Conventional cancer therapies, such as surgery and chemotherapy, have significant limitations and frequently fail to produce satisfying results. AuNPs have a prolonged circulation time, allow easy modification with ligands detected via cancer cell surface receptors, and increase uptake through receptor-mediated endocytosis. To exploit these unique features, studies have been carried out on the use of AuNPs as contrast agents for X-ray-based imaging techniques (i.e., computed tomography). As nanocarriers, AuNPs synthesized by nontoxic and biocompatible plants to deliver therapeutic biomolecules could be a significant stride forward in the effective treatment of various cancers. Fluorescent-plant-based markers, including AuNPs, fabricated using Medicago sativa, Olax Scandens, H. ambavilla, and H. lanceolatum, have been used in detecting cancers. Moreover, green synthesized AuNPs using various extracts have been applied for the treatment of different types of solid tumors. However, the cytotoxicity of AuNPs primarily depends on their size, surface reactivity, and surface area. In this review, the benefits of plant-based materials in cancer therapy are firstly explained. Then, considering the valuable position of AuNPs in medicine, the application of AuNPs in cancer therapy and detection is highlighted with an emphasis on limitations faced by the application of such NPs in drug delivery platforms.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Application to cancer therapy"

1

Roberts, Fiona L. "Cancer therapy : origin and application." Thesis, University of Strathclyde, 2012. http://oleg.lib.strath.ac.uk:80/R/?func=dbin-jump-full&object_id=16930.

Full text
Abstract:
In this thesis we use mathematical techniques to model two biological systems. First, we examine the growth dynamics of the antibiotic producing bacteria Streptomyces coelicolor and present a system of PDEs. We study the system both numerically and analytically. Due to oscillations in the numerical solution when solved using NAG, which uses a finite difference discretization, we change to a finite element discretization which corrects the oscillations. S. coelicolor also produces anticancer drugs, these can be encapsulated during the self-assembly of nanometre-sized vesicles, BPVs (biomimetic polymer vesicles) which are used as a novel targeted cancer therapy. We present a system of ODEs that focuses on the binding kinetics between cell-surface receptors and targeting molecules (ligands) on the BPV. We solve the system numerically, showing there is an optimal number of ligands per BPV for optimal uptake by tumour cells. We extend the model to allow for the infiltration of BPVs into tumour spheroids. Numerical solutions show that the growth of the spheroid is linear if the therapeutic BPVs are absent, and slows in the other case (for some parameter values). Using large time asymptotics we explore regions of parameter space where either steady states or travelling waves will occur.
APA, Harvard, Vancouver, ISO, and other styles
2

Roslan, Nuruliza. "Inhibiting Tumor Protein D52 function for anti-cancer therapy application." Thesis, The University of Sydney, 2013. http://hdl.handle.net/2123/9437.

Full text
Abstract:
Tumor protein D52 (TPD52) is amplified and/or overexpressed in many cancer types. Previously, TPD52 expression has been associated with ERBB2, suggesting these oncogenes may co-operate in cancer pathogenesis. Furthermore, as ERBB2 is known to promote lipogenesis, this led us to hypothesize that TPD52 expression may be associated with lipogenic phenotypes. RNA interference approaches investigated the effects of depleting TPD52 and ERBB2 in breast cancer cell lines with differing TPD52 and ERBB2 gene amplification and/or expression status. Transient TPD52 knock-down in the ERBB2-amplified breast cancer cell lines SK-BR-3 and BT-474 produced significant apoptosis. Unlike ERBB2 knock-down, transient TPD52 knock-down produced no reduction in pAKT levels. Multiple SK-BR-3 cell lines were generated in which TPD52 levels were stably reduced, showed significant inverse correlations between pERBB2 and TPD52 levels in viable TPD52-depleted and control cell lines. Fluorescent staining (BODIPY 493/503) showed increased lipid droplet numbers and sizes in TPD52- but not TPD52L1-transfected 3T3 cell lines relative to controls, as measured by fluorescent intensity. This study therefore identified TPD52 as a survival factor in ERBB2-amplified breast cancer cell lines, and provided the first direct evidence for TPD52 involvement in regulating cellular lipid storage.
APA, Harvard, Vancouver, ISO, and other styles
3

Cheng, Wing-Shing. "TARP Promoter-Based Prostate Cancer Gene Therapy : From Development to Application." Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2005. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5736.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hobson, N. J. "Nanoparticle theranostics for applications in cancer diagnostics and cancer therapy." Thesis, University College London (University of London), 2017. http://discovery.ucl.ac.uk/1546610/.

Full text
Abstract:
Traditionally, medicine has been conducted using a diagnostic procedure followed by an appropriate therapy and monitored were possible. On the whole, these steps have happened independently of each other. In recent years however many have started to question this independent approach and have asked whether technologies that seek to combine diagnostics and therapies would be more beneficial at treating diseases. This new medical discipline has been termed theranostics. The aim of this project was to design and synthesise a novel theranostic nanoparticle, using a micelle forming amphiphilic carbohydrate, with the overall hypothesis of determining whether using a nanomedicine that can simultaneously image and treat would improve the effectiveness of a cancer treatment. Super paramagnetic iron oxide nanoparticles (IONPs) have gained considerable attention as an MRI contrast agent due to their unique magnetic properties and relatively inoffensive toxicity profile. Before IONPs may be used in a biological environment they must overcome several challenges, including being stable to aggregation and organ targeting. In this project a modified chitosan amphiphilic polymer was used to successfully formulate IONPs into colloidal stable aqueous dispersions using two different methods which produced blackberry nanoparticles and raspberry nanoparticles. The raspberry nanoparticles were extensively characterised in vitro and in vivo and were found to be highly effective as an MRI imaging probe for the liver and spleen. Following this, they were tested for their cancer imaging properties in an in vivo mouse tumour model. The drug loading capacity of the raspberry nanoparticles was investigated using lomustine, paclitaxel and methotrexate, however no effective drug encapsulation was determined in this project. Overall, a highly effective MRI probe was engineered and characterised, although its future success will be determined by its activity towards a disease target.
APA, Harvard, Vancouver, ISO, and other styles
5

Hawwa, Ahmed Fayeq. "Application of pharmacokinetics and pharmacogenomics to tailor anti-cancer and immunosuppressive therapy." Thesis, Queen's University Belfast, 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.486218.

Full text
Abstract:
In the research presented in this thesis, the application of pharmacokinetic principles and pharmacogenetic tools to enhance therapeutic drug monitoring of the anti-cancer and immunosuppressive medications (6-MP and AZA) in two patient populations (paediatric patients with ALL and adults with IBD) was investigated. Before a pharmacokinetic analysis was conducted, a valid and reliable microanalytical method for the rapid, simultaneous and accurate determination of 6-MP and four of its metabolites from small volumes (200JlL) of plasma and erythrocytes was developed (Chapter 2). The developed method was successfully applied to the analysis of 75 samples from 19 paediatric patients with ALL and 44 samples from 35 adult patients with IBD. The association between the measured metabolite levels and the ·allelic variations of 3 enzymes involved in 6-MP metabolism (XO, TPMT and ITPA) was examined (Chapter 3). In addition, the association between the studied variants and the occurrence of myelotoxicity and haematological parameters was evaluated. This contributed to a clearer understanding of 6-MP metabolism and showed important pharmacogenetic associations. Furthermore, it threw light on potential genetic. characteristics that may contribute to higher risk of adverse events. In Chapter 4, the individual relationships between 6-MP and its metabolites and the correlations between these metabolites and dose, haematological parameters or the incidence of various forms of myelotoxicity in ALL and IBD patients were evaluated. The intra- and inter-patient variability in 6~MP metabolite concentrations were utilised to investigate the different factors that could lead to this variation via constructing a population pharmacokinetic model from the metabolite concentrations measured. The model offered a more rational dosing approach than the traditional empirical method since it combin~d the current practice of using body surface area in 6-MP dosing with a pharmacogenetically guided dosing based on TPMT genotype. In Chapter 5, adherence to 6-MP/AZA in ALL and IBD patients was evaluated via examining red blood cell and plasma levels of drug and metabolites. In addition, adherence questionnaires completed by patients or their parents (in case of children) and therapeutic outcome measures (as assessed by haematological parameters, myelotoxicity or activity indices) were used to assess adherence in the same cohort of patients. The study demonstrated non-adherence to medication in both ALL and IBD populations and highlighted the need for programmes to help these patients better !lndefstand their disease and for the implementation of disease-specific interventions to improve medication adherence.
APA, Harvard, Vancouver, ISO, and other styles
6

Silva, Ana Sofia Matias da. "Design and production of new nanodevices for future application in cancer therapy." Master's thesis, Universidade da Beira Interior, 2011. http://hdl.handle.net/10400.6/1054.

Full text
Abstract:
Nanotechnology is a multidisciplinary area of research that involves different knowledgements from, like life sciences, engineering and medicine. It has been used for different applications such as molecular imaging, molecular diagnosis and also targeted therapy. So far, ddifferent nanoscale devices have been produced, among them, inorganic nanoparticles, dendrimes, lipossomes, polymeric micelles, polymeric nanoparticles, nanotubes and nanofibers are some of the examples. Some of these particles exhibit unique optical and electrical properties allowing their course identification and precise location in the body. Gold nanoparticles are an example of inorganic particles with exceptional physico-chemical properties that demonstrate a huge potential for biomedicine applications. The present study aimed to produce gold nanoparticles by two different methods: the citrate reduction method developed by Frens in 1973 (method 1), and its functionalization with oligoaziridine, developed by the colleagues from Universidade Nova de Lisboa, as a capping agent (method 2). This second method relies on the fact that gold nanoparticles can be prepared in water directly by the complexation of the alkylamine molecules that act as reducing agents and consequently stabilizes gold nanoparticles. Moreover, gold nanoparticles produced by method 1 were also grafted with homofunctional maleimide poly(ethylene glycol) and then capped with oligoaziridine and the same parameters mentioned above were also evaluated. The cytotoxicity and cell internalization of the different nanoparticles herein produced, was evaluated through in vitro studies. The use of this new biosensor allow us to confirm the entry of the produced nanoparticles into cells opening new sights for the use of these particles as drug/gene delivery agents and/or as a new method for optimal imaging when methodologies like X-ray computed tomography or magnetic resonance cannot be used.
A nanotecnologia é uma área de investigação multidisciplinar que abrange conhecimentos das ciências da vida, da engenharia e da medicina. Esta área do conheciemnto tem contribuido para melhorar as tecnologias de imagiologia, diagnóstico molecular e na terapia direccionada. Nos últimos anos têm sido produzidos diferentes dispositivos à nanoescala, entre eles destacam-se as nanopartículas inorgânicas, dendrímeros, lipossomas, micelas poliméricas, nanopartículas poliméricas, nanotubos e nanofibras. As nanopartículas de ouro são um exemplo de partículas inorgânicas, e apresentam propriedades físicas e químicas excepcionais que lhe conferem um elevado potencial para aplicações biomédicas. O presente estudo teve como objectivo produzir nanopartículas de ouro por dois métodos diferentes: o método de redução de citrato desenvolvido por Frens em 1973 (método 1); e o da funcionalização das aminas através da adição de oligoaziridina, um biosensor desenvolvido pelos colegas da Universidade Nova de Lisboa, como agente de revestimento (método 2). Este segundo método envolve a preparação das nanopartículas de ouro directamente em água através da complexação com moléculas acilaminas, que actuam como agentes redutores, estabilizando as nanopartículas de ouro. Numa segunda fase, as nanopartículas de ouro produzidas pelo método 1 foram revestidas com polietilenoglicol maleimida homofuncional e, em seguida, adiciounou-se oligoaziridine. A citoxicidade e a capacidade de entrarem nas células foi tambem avaliada para estas nanopartículas. Os resultados obtidos demonstram que o polimero polietilenoglicol maleimida homofuncional se liga de uma forma efectiva às nanopartículas de ouro. Por outro lado, provou-se que o oligoaziridine se liga tanto ao polietilenoglicol como às nanopartículas isoladas. Após a sintese das nanopartículas pelos dois métodos foi avaliada a sua toxicidade e a capacidade de entrarem nas células eucarióticas. A utilização deste novo biosensor permite confirmar a entrada das nanopartículas nas células, o que possibilitará o uso destas partículas como agentes de entrega direccionada de fármacos, genes ou como um novo método para a obtenção de imagens quando metodologias como Tomografia Computadorizada por raios X ou Ressonância Magnética não poderem ser usadas.
APA, Harvard, Vancouver, ISO, and other styles
7

Tsedev, Uyanga. "Engineering M13 bacteriophage platforms for cancer therapy applications." Thesis, Massachusetts Institute of Technology, 2015. http://hdl.handle.net/1721.1/103838.

Full text
Abstract:
Thesis: S.M., Massachusetts Institute of Technology, Department of Mechanical Engineering, 2015.
Cataloged from PDF version of thesis.
Includes bibliographical references (pages 46-48).
Two novel schemes for engineering M13 bacteriophage for application in the diagnosis, imaging and treatment of human tumors are proposed. Firstly, by exploiting the uniquely malleable biology of the M13 filamentous phage, we have engineered filamentous phages of shorter lengths by constructing our own set of small viral ssDNA that are packaged by M13 capsid proteins. These 'inho' phages can be sized to ~50nm and above in length. The small phage retains the M13 major and minor coat proteins which have previously been manipulated to serve as tethers to carry various therapy and imaging agents and target specific cancer sites. Now with the ability to control the aspect ratio of these rigid, rod-like phages we can further improve on M13 based cancer detection by optimizing for phage blood circulation and tumor extravasation. Secondly, we have added to our cancer targeting M13 platform collection by cloning for chlorotoxin display on the tail p3 capsid protein of M13. Chlorotoxin can induce passage across blood-brain barrier, targets for cancer cells, and specifically internalizes to glioma cells. Expression of chlorotoxin on M13 will allow us to capitalize on its strong affinity for tumors of neuroectodermal origin and expand the M13 therapy and imaging platform to tumor masses in the brain.
by Uyanga Tsedev.
S.M.
APA, Harvard, Vancouver, ISO, and other styles
8

Hauser, Anastasia K. "PEPTIDE-FUNCTIONALIZED MAGNETIC NANOPARTICLES FOR CANCER THERAPY APPLICATIONS." UKnowledge, 2016. http://uknowledge.uky.edu/cme_etds/59.

Full text
Abstract:
Lung cancer is one of the leading causes of cancer deaths in the United States. Radiation and chemotherapy are conventional treatments, but they result in serious side effects and the probability of tumor recurrence remains high. Therefore, there is an increasing need to enhance the efficacy of conventional treatments. Magnetic nanoparticles have been previously studied for a variety of applications such as magnetic resonance imaging contrast agents, anemia treatment, magnetic cell sorting and magnetically mediated hyperthermia (MMH). In this work, dextran coated iron oxide nanoparticles were developed and functionalized with peptides to target the nanoparticles to either the extracellular matrix (ECM) of tumor tissue or to localize the nanoparticles in subcellular regions after cell uptake. The magnetic nanoparticles were utilized for a variety of applications. First, heating properties of the nanoparticles were utilized to administer hyperthermia treatments combined with chemotherapy. The nanoparticles were functionalized with peptides to target fibrinogen in the ECM and extensively characterized for their physicochemical properties, and MMH combined with chemotherapy was able to enhance the toxicity of chemotherapy. The second application of the nanoparticles was magnetically mediated energy delivery. This treatment does not result in a bulk temperature rise upon actuation of the nanoparticles by an alternating magnetic field (AMF) but rather results in intracellular damage via friction from Brownian rotation or nanoscale heating effects from Neél relaxations. The nanoparticles were functionalized with a cell penetrating peptide to facilitate cell uptake and lysosomal escape. The intracellular effects of the internalized nanoparticles alone and with activation by an AMF were evaluated. Iron concentrations in vivo are highly regulated as excess iron can catalyze the formation of the hydroxyl radical through Fenton chemistry. Although often a concern of using iron oxide nanoparticles for therapeutic applications, these inherent toxicities were harnessed and utilized to enhance radiation therapy. Therefore, the third application of magnetic nanoparticles was their ability to catalyze reactive oxygen species formation and increase efficacy of radiation. Overall, iron oxide nanoparticles have a variety of cancer therapy applications and are a promising class of materials for increasing efficacy and reducing the side effects of conventional cancer treatments.
APA, Harvard, Vancouver, ISO, and other styles
9

Huth, Christopher. "Development of Multifunctional Nanoparticles for Cancer Therapy Applications." University of Cincinnati / OhioLINK, 2012. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1352401861.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

JAFER, RASHIDA. "Laser plasma protons and applications in cancer therapy and proton radiography." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2009. http://hdl.handle.net/10281/7457.

Full text
Abstract:
Recent developments in high power, ultrashort pulse laser systems enable laser intensities beyond 10^21 W/cm^2 to be achieved. When focused onto thin foil targets, plasmas with extremely high electrostatic fields (>10^12V/m) are produced, resulting in the acceleration of protons/ions to very high energies (~60MeV). During my PhD, I have worked on experimental investigations into proton acceleration driven by high power laser pulses. Key to successful deployment of laser proton sources one one side is getting higher proton energies through to achieve the ultimate goal of realising table top machines for the treatment of cancer and on the other side, optimising the beam quality, an objective that was of the main motivation for my PhD work. My two main achievements were: 1. The production of bright, ultrashort and radially smooth pulsed proton beams using laser heating of pre-plasmas formed with long (nanosecond) pulses with ultrahigh intensity picosecond pulses. 2. Use of these beams to study the ultrafast dynamics of target implosion under intense laser irradiation The experiments on proton acceleration with the specific goal of controlling the proton beam quality by optical tool design, were performed at RAL. This scheme involves the use of multiple laser pulses to enhance and control the properties of beams of protons accelerated in ultra-intense laser irradiation of planar foil targets. Specifically, one laser pulse produces and controls the expansion of the target to enhance the energy coupling to the main (delayed) laser and/or drives shock deformation of the target to change the direction of the proton beam. The preplasma formed by this low intensity nanosecond beam (~ 0.5-5x10^12 W/cm^2) was used to enhance the laser absorption of the main (delayed) CPA (Chirped pulse amplified). The main CPA picosecond beam was used at high intensity (~ 4x 10^20 W /cm^2) to produce intense proton beams from the hydrogen rich target. The optimum intensity of the nanosecond beam was investigated and optimised to yield a very smooth and circular distribution of the proton beam achieved using a second long pulse laser at 5x10^12w/cm^2. The second achievement concerns an experiment also performed at RAL on proton radiography. As the laser based protons are characterised by small source size, high degree of collimation and short duration, they can be used in point projection backlighting schemes to perform radiography. In particular, I used this idea to perform radiography of a cylindrical target ~ 200µm long imploding under irradiation by long laser pulses of nanosecond duration. This allows measuring the degree of compression of the target as well as the stagnation time in the dynamic regime. The experiment took place in the framework of the HiPER project (the European High Power laser Energy Research facility Project). The final goal of the experiment was to study the transport of fast electron in cylindrical compressed target a subject of interest for fast ignition. In parallel to proton radiography x-ray radiography was used to compare the results. One of the specific advantages of using laser generated protons is that their spectrum is continuous upto a high energy cutoff. Because of their different time of flights protons proved to be very effective in revealing the implosion history of the target. In principle, the obtained implosion can be followed in time with a single shot sensitivity. Instead x-ray radiograph gives one image per laser shot at one fixed time and one has to make several shots in order to reveal the complete history of implosion. Another advantage of using proton radiography is a simpler experimental setup keeping imploding cylinder between proton target and proton detector on the same axis. Simulations of formation of proton images were made with the Monte Carlo MCNPX Code using the density profiles of the imploded cylinder obtained with the 2D-hydro CHIC code. A detailed study of Multiple Coulomb Scattering and Stopping Powers of the protons in low energy regimes for cold and warm matter was done to interpret the experimental results. Finally, I’m taking part in the analysis of experimental results obtained at the University of Rochester (USA) on the Omega-EP laser, and concerning magnetic field effect on the proton radiographs of a wired cone.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Application to cancer therapy"

1

1930-, Sluyser M., ed. Application of apoptosis to cancer treatment. Dordrecht: Springer, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

1930-, Sluyser M., ed. Application of apoptosis to cancer treatment. Dordrecht: Springer, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Koji, Kawakami, Aggarwal Bharat B. 1950-, and Puri Raj K, eds. Cytotoxins and immunotoxins for cancer therapy: Clinical applications. Boca Raton: CRC Press, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

1942-, Henderson Barbara W., and Dougherty Thomas J. 1933-, eds. Photodynamic therapy: Basic principles and clinical applications. New York: M. Dekker, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kelley, Mark Richard. DNA repair in cancer therapy: Molecular targets and clinical applications. London: Elsevier/Academic Press, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

DNA repair in cancer therapy: Molecular targets and clinical applications. London: Elsevier/Academic Press, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

E, Bergsagel Daniel, and Mak Tak W. 1945-, eds. Molecular mechanisms and their clinical application in malignancies. San Diego: Academic Press, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

H, Levitt Seymour, Khan Faiz M, and Potish Roger A, eds. Levitt and Tapley's technological basis of radiation therapy: Practical clinical applications. 2nd ed. Philadelphia: Lea & Febiger, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Meijnders, Paul Joseph Nikolas. The application of rat lung tumour models in experimental therapy of bronchial cancer =: Toepassing van rattenlongtumormodellen in experimentele therapie van longkanker. [Leiden: University of Leiden], 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

H, Levitt Seymour, and Tapley Norah duV 1921-, eds. Levitt and Tapley's technological basis of radiation therapy: Clinical applications. 3rd ed. Philadelphia: Williams & Wilkins, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Application to cancer therapy"

1

Ganser, A., B. Völkers, J. Greher, F. Walther, and D. Hoelzer. "Application of Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Malignant Hematological Diseases." In Cancer Therapy, 90–95. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-73721-3_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Lauer, Ulrich M., Can Yurttas, and Julia Beil. "Novel Biological Therapies with Direct Application to the Peritoneal Cavity." In Cancer Regional Therapy, 17–26. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-28891-4_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Nishihara, Hideaki, and Keiji Kanda. "Procedures for the Medical Application of Research Reactors." In Cancer Neutron Capture Therapy, 257–60. Boston, MA: Springer US, 1996. http://dx.doi.org/10.1007/978-1-4757-9567-7_38.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Jain, Kewal K. "Personalized Cancer Therapy." In Applications of Biotechnology in Oncology, 671–824. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-9245-0_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Chirathaworn, Chintana, and Yong Poovorawan. "IL-18 in Regulation of Antitumor Immune Response and Clinical Application." In Targeted Cancer Immune Therapy, 19–41. New York, NY: Springer New York, 2009. http://dx.doi.org/10.1007/978-1-4419-0170-5_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Banno, Kouji, Miho Iida, Megumi Yanokura, Iori Kisu, Kanako Nakamura, Masataka Adachi, Takashi Iwata, Kyoko Tanaka, and Daisuke Aoki. "Application of MicroRNA in the Treatment and Diagnosis of Cervical Cancer." In MicroRNA Targeted Cancer Therapy, 129–37. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-05134-5_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Dariya, Begum, and Ganji Purnachandra Nagaraju. "Application of Single Cell Technology in Colorectal Cancer." In Colon Cancer Diagnosis and Therapy, 1–13. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-64668-4_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Itasaka, Satoshi. "Clinical Application of IMRT for Cervical Esophageal Cancer." In Intensity-Modulated Radiation Therapy, 289–99. Tokyo: Springer Japan, 2015. http://dx.doi.org/10.1007/978-4-431-55486-8_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Verma, Rama Shanker, Sirisha Potala, Mrudula Mathew, and Swati Choudhary. "Application of Microbial Toxins for Cancer Therapy." In Microorganisms in Sustainable Agriculture and Biotechnology, 647–62. Dordrecht: Springer Netherlands, 2011. http://dx.doi.org/10.1007/978-94-007-2214-9_28.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Mozafari, Faezeh, Hamid Rashidzadeh, Murat Barsbay, Mohammadreza Ghaffarlou, Marziyeh Salehiabar, Ali Ramazani, Morteza Abazari, et al. "Application of Nanoradioprotective Agents in Cancer Therapy." In Harnessing Materials for X-ray Based Cancer Therapy and Imaging, 175–200. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-04071-9_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Application to cancer therapy"

1

Ding, Hao, Mengyu Jia, Weiya Wang, Lihong Yang, Pengpeng Qu, Feng Gao, and Huijuan Zhao. "A Cervical Cancer Screening System and the Clinical Application." In Cancer Imaging and Therapy. Washington, D.C.: OSA, 2016. http://dx.doi.org/10.1364/cancer.2016.jtu3a.34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Nandy, Sreyankar, Atahar Mostafa, Patrick D. Kumavor, and Quing Zhu. "Application of spatial frequency domain imaging for characterizing wide field tissue optical heterogeneity." In Cancer Imaging and Therapy. Washington, D.C.: OSA, 2016. http://dx.doi.org/10.1364/cancer.2016.jm3a.1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Verdecchia, Kyle, Mamadou Diop, Laura B. Morrison, Ting-Yim Lee, and Keith St. Lawrence. "Application of a Three-Layer Model to Multi-Distance Diffuse Correlation Spectroscopy: Validation Experiments in Pigs." In Cancer Imaging and Therapy. Washington, D.C.: OSA, 2016. http://dx.doi.org/10.1364/cancer.2016.jw3a.40.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Diller, Marie-Luce. "Fluorescence detection system using a krypton laser: application to cancer diagnosis in photodynamic therapy." In Photodynamic Therapy of Cancer II. SPIE, 1995. http://dx.doi.org/10.1117/12.199153.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Levenson, Richard, Zachary Harmany, and Farzad Fereidouni. "Histopathology Methods, Assays and their Applications." In Cancer Imaging and Therapy. Washington, D.C.: OSA, 2016. http://dx.doi.org/10.1364/cancer.2016.cth1a.1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Keidar, Michael. "Cold plasma application in cancer therapy." In 2016 IEEE International Conference on Plasma Science (ICOPS). IEEE, 2016. http://dx.doi.org/10.1109/plasma.2016.7534292.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Orenstein, Arie. "Photodynamic therapy of human skin tumors using topical application of 5-aminolevulinic acid, dimethylsulfoxide (DMSO), and edetic acid disodium salt (EDTA)." In Photodynamic Therapy of Cancer II. SPIE, 1995. http://dx.doi.org/10.1117/12.199178.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Krolopp, Ádám, Attila Csákányi, Dóra Haluszka, Lajos Vass, Norbert Wikonkál, and Róbert Szipőcs. "FiberScope: an Optical Fiber Laser Based, Handheld 3D Nonlinear Microscope System for in vivo Diagnostic Applications in Dermatology and Nanomedicine." In Cancer Imaging and Therapy. Washington, D.C.: OSA, 2016. http://dx.doi.org/10.1364/cancer.2016.jtu3a.55.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Sztejnberg, Manuel L., and Tatjana Jevremovic. "Advanced Application of BNCT in Advanced Cancers." In 17th International Conference on Nuclear Engineering. ASMEDC, 2009. http://dx.doi.org/10.1115/icone17-75906.

Full text
Abstract:
We present a new concept of one form of radiation binary targeted therapy that may offer hope for the often fatal relapsed and/or metastasized HER2+ cancers. The idea is to deliver boronated (boron-10 isotope) anti-HER2 monoclonal antibodies (mAbs) to the patient to be deposited preferentially into the tumor followed by one session of a low energy neutron irradiation. Based on actual computed tomography data, we present the comprehensive theoretical (numerical) modeling of the new approach in designing the treatment conditions for the boron neutron capture therapy (BNCT) using the MITRII-FCB neutron beam facility. The results show the effectiveness of the proposed treatment option for the advanced breast cancers and the metastasized breast cancers in the lungs of a patient. Our theoretical analysis concludes that with a boron concentration of ∼316 μg/g in tumor and a tumor-to-healthy tissue boron concentration ratio of 35:1, this new BNCT breast cancer treatment can be performed with very low doses to normal tissue and 50 Gy, or higher, doses delivered to the tumor regions. In particular, when applied to the breast cancer treatment, the resulting doses to skin and lung remain under the tolerance dose values. We also went beyond the traditional application of the BNCT and analyzed its applicability in targeting the metastasized breast cancer; using the same theoretical approach we determined the doses delivered into the patient lung with scattered cancer loci.
APA, Harvard, Vancouver, ISO, and other styles
10

Yue, Xiling, Ciceron O. Yanez, Sheng Yao, and Kevin D. Belfield. "PAG-based Photodyanmic Therapy in Cancer Cells." In Bio-Optics: Design and Application. Washington, D.C.: OSA, 2013. http://dx.doi.org/10.1364/boda.2013.jt2a.38.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Application to cancer therapy"

1

Dropulic, Lesia. Development of Targeted Sindbis Virus Vectors for Potential Application to Breast Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, September 2001. http://dx.doi.org/10.21236/ada404597.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Dropulic, Lesia K. Development of Targeted Sindbis Virus Vectors for Potential Application to Breast Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, September 2002. http://dx.doi.org/10.21236/ada411347.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Dropulic, Lesia K. Development of Targeted Sindbis Virus Vectors for Potential Application to Breast Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, September 2003. http://dx.doi.org/10.21236/ada424055.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Dropulie, Lesia K. Development of targeted Sindbis Virus Vectors for Potential Application to Breast Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, October 2000. http://dx.doi.org/10.21236/ada392586.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Wilbur, D. Scott. Development of Reagents for Application of At-211 to Targeted Radionuclide Therapy of Cancer. Office of Scientific and Technical Information (OSTI), December 2011. http://dx.doi.org/10.2172/1032019.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Reiter, Robert. Mechanism of Action of Prostate Stem Cell Antigen Targeted Antibody Therapy and Its Relevance to Clinical Application in Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, January 2009. http://dx.doi.org/10.21236/ada512783.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Clarke, Robert S. Endocrine Therapy of Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, June 2005. http://dx.doi.org/10.21236/ada443230.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Clarke, Robert. Endocrine Therapy of Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, June 2008. http://dx.doi.org/10.21236/ada492475.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Gallion, Holly. Advances in Breast Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, June 2010. http://dx.doi.org/10.21236/ada535545.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Gallion, Holly. Advances in Breast Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, June 2009. http://dx.doi.org/10.21236/ada510052.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Application to cancer therapy' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography